Trial Profile
A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Jul 2014 New trial record